10	
1	د
	1

	Application No.	Applicant(s)	_
	09/779,957	SNELL, KRISTI D.	
Notice of Allowability	Examiner	Art Unit	_
	Stuart F. Baum	1638	
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS Is herewith (or previously mailed), a Notice of Allowance (PTOL-88 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT I of the Office or upon petition by the applicant. See 37 CFR 1.31	S (OR REMAINS) CLOSED in 5) or other appropriate comm RIGHTS. This application is:	n this application. If not included unication will be mailed in due course. THIS	;
1. $igtimes$ This communication is responsive to <u>papers filed 1/24/20</u>	<u>005</u> .		
2. X The allowed claim(s) is/are <u>1, 6-15, 18, 20-28 (renumber</u>	<u>1-21)</u> .		
3. $igotimes$ The drawings filed on <u>12 April 2002</u> are accepted by the	Examiner.		
4. Acknowledgment is made of a claim for foreign priority of a) All b) Some* c) None of the:  1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority of International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE noted below. Failure to timely comply will result in ABANDON THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5. A SUBSTITUTE OATH OR DECLARATION must be sub INFORMAL PATENT APPLICATION (PTO-152) which give the company of the Notice of Draftspering including changes required by the Notice of Draftspering including changes required by the attached Examine Paper No./Mail Date  [b) including changes required by the attached Examine Paper No./Mail Date  [content of the priority documents have sub including changes required by the attached Examine Paper No./Mail Date  [dentifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in the department of the pattached Examiner's comment regarding REQUIREMEN'	ve been received. ve been received in Application locuments have been received in the header according to 37 Citosit of BIOLOGICAL MAT	on No  Indicate the distribution of the drawings in the front (not the back) of FR 1.121(d).  Indicate the distribution of the drawings in the front (not the back) of FR 1.121(d).  Indicate the distribution of the drawings in the submitted. Note the	
Attachment(s)  1.  Notice of References Cited (PTO-892)  2.  Notice of Draftperson's Patent Drawing Review (PTO-948)  3.  Information Disclosure Statements (PTO-1449 or PTO/SB Paper No./Mail Date  4.  Examiner's Comment Regarding Requirement for Deposit of Biological Material	) 6. ⊠ Interview S Paper No. 8/08), 7. ⊠ Examiner's	nformal Patent Application (PTO-152) Summary (PTO-413), /Mail Date <u>0205</u> . s Amendment/Comment s Statement of Reasons for Allowance	
		Stuart F. Baum	

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04)

Application/Control Number: 09/779,957 Page 2

Art Unit: 1638

## **EXAMINER'S AMENDMENT**

## RCE Acknowledgment

1. The request filed on 1/24/2005 for a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114, based on parent Application No. 09/779,957 is acceptable and a RCE has been established.

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Brian K. Adams on 2/22/2005.

## 3. IN THE CLAIMS:

- --1. A DNA construct for expression of multiple gene products in a cell comprising:
  - (a) a single promoter at the 5' end of the construct [,];
- (b) an intein splicing unit comprising two or more extein sequences encoding one or more separate proteins, and one or more intein sequences fused to the carboxy-terminus encoding portion of each extein sequence, except the last extein sequence to be expressed[,]; and
- (c) a 3' termination sequence comprising a polyadenylation signal following the last extein protein coding sequence[,];

wherein the intein splicing unit is expressed as a precursor protein containing at least one intein flanked by extein encoded proteins; and wherein at least one of the inteins can

Application/Control Number: 09/779,957 Page 3

Art Unit: 1638

catalyze excision of the exteins; and wherein at least one amino acid residue is substituted in, or

added to, the intein splicing unit so that the excised exteins are not ligated by the intein.--

--7. The construct of claim 1 wherein the extein sequences encoding one or more

separate proteins are preceded or followed by a sequence encoding a peptide that targets the gene

expression product to a particular compartment within the cell in which the construct is

expressed.--

--15. A method for expressing multiple genes in cells comprising transforming the cells

with a DNA construct comprising:

(a) a single promoter at the 5' end of the construct[,];

(b) an intein splicing unit comprising two or more extein sequences encoding

one or more separate proteins, and one or more intein sequences fused to the carboxy-terminus

encoding portion of each extein sequence, except the last extein sequence to be expressed[,]; and

(c) a 3' termination sequence comprising a polyadenylation signal following

the last extein protein coding sequence;

wherein the intein splicing unit is expressed as a precursor protein containing at

least one intein flanked by extein encoded proteins; and wherein at least one of the inteins can

catalyze excision of the exteins; and wherein at least one amino acid residue is substituted in, or

added to, the intein splicing unit so that the excised exteins are not ligated by the intein.--

Application/Control Number: 09/779,957

Art Unit: 1638

--21. The method of claim 15 wherein the extein sequences encoding one or more

separate proteins are preceded or followed by a sequence encoding a peptide that targets the gene

expression product to a particular compartment within the cell in which the construct is

expressed.--

--24. The method of claim 15 wherein the intein splicing unit expression product

prevents the ligation reactions normally associated with protein splicing.--

4. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Stuart F. Baum whose telephone number is 571-272-0792. The

examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Amy Nelson can be reached on 571-272-0804. The fax phone number for the

organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 571-272-1600.

Stuart F. Baum Ph.D.

Patent Examiner

Art Unit 1638

February 22, 2005

ELIZABETH MICELWAIN
PRIMARY EXAMINER

Page 4